SEC Company Response from NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) (CIK 0000810509) — Aug 2, 2022
NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) (CIK 0000810509)
Date: Aug. 2, 2022 · CIK: 0000810509 · Accession: 0001437749-22-018476
AI Filing Summary & Sentiment
File numbers found in text: 333-262691
Letter
navb20220802_corresp.htm
August 2, 2022
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Tim Buchmiller, Staff Attorney
Re: Navidea Biopharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-262691
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-1 (File No. 333-262691) (the “Registration Statement”) to become effective at 4:30 p.m. Eastern Time on August 3, 2022, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Bill Mower of Maslon LLP, counsel to the registrant, at (612) 672-8358.
Very truly yours,
NAVIDEA BIOPHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm navb20220802_corresp.htm August 2, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Tim Buchmiller, Staff Attorney Re: Navidea Biopharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-262691 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-1 (File No. 333-262691) (the “Registration Statement”) to become effective at 4:30 p.m. Eastern Time on August 3, 2022, or as soon thereafter as is practicable. Once the Registration Statement has been declared effective, please orally confirm that event with Bill Mower of Maslon LLP, counsel to the registrant, at (612) 672-8358. Very truly yours, NAVIDEA BIOPHARMACEUTICALS, INC. By: /s/ Michael S. Rosol Michael S. Rosol, Ph.D. Chief Medical Officer (Principal Executive Officer) cc: William M. Mower, Maslon LLP